Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee
Launched by IDEA AG · Apr 21, 2006
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
This is a multicenter, randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), double-dummy, parallel group, placebo- and active-controlled study to determine the safety and effectiveness of 110 mg of ketoprofen in Transfersome, applied to the skin, in subjects experiencing at least moderate pain when not taking analgesic medication secondary to osteoarthritis pain of the knee. The study hypothesis is that ketoprofen in Transfersome applied to the skin twice...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Osteoarthritis of the knee for a minimum of six months
- • Patient´s rating of pain in the index knee while not taking oral NSAIDs of at least 3 using a 5-point Likert scale
- • Presenting two out of the three following criteria - Morning stiffness of less than 30 minutes duration, Crepitus on motion, Age \>= 40 years
- • Patients must have used oral NSAIDs at least 3 days per week for the 3 months prior to screening or the patient was taking an NSAID on a regular basis (\>25 out of 30 days) at a therapeutic level for at least 30 days prior to screening
- • Each of the following three criteria (the osteoarthritis flare criteria) must be met - Index knee pain assessment at walking at least 40 mm on VAS at baseline, Increase of index knee pain at walking by at least 15 mm on VAS at baseline compared to screening, Physician´s global assessment of osteoarthritis 3-5 and at least 1 grade increase from screening
- Exclusion Criteria:
- • Grade 1 or Grade 4 severity of the index knee based on Kellgren and Lawrence radiographic criteria
- • Intraarticular injections or arthroscopy of the index knee within 3 months prior to screening
- • Signs of any clinically important inflammation of the index knee including redness, warmth and or a large bulging effusion with the loss of normal contour
- • Crystalline-induced synovitis in the index knee
- • History, physical examination or radiographic suggestive of acute inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic arthritis, gout, pseudogout, fibromyalgia, lupus erythematosus, or other types of inflammatory arthritis of the index knee
About Idea Ag
idea ag is an innovative clinical trial sponsor dedicated to advancing healthcare through the development and management of cutting-edge research initiatives. With a focus on enhancing patient outcomes, idea ag collaborates closely with healthcare professionals, regulatory bodies, and industry partners to design and implement robust clinical trials. The organization leverages a wealth of expertise in trial design, data management, and regulatory compliance to ensure the highest standards of quality and integrity in its research endeavors. Committed to fostering scientific advancements, idea ag aims to bring transformative therapies to market, ultimately improving the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
McNeil Consumer & Specialty Pharmaceuticals Clinical Trial
Study Director
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials